Generic Medicine Info
Undiagnosed vaginal bleeding; severe osteoporosis (for use in severe sexual deviation in men). Pregnancy and lactation.
Special Precautions
Patient with history of QTc prolongation, heart failure, congenital long QT syndrome, frequent electrolyte abnormalities; risk factors for osteoporosis or decreased bone mineral density (e.g. family history of osteoporosis, prolonged use of agents that reduce bone mineral density, malnutrition, smoking, chronic alcohol abuse); known or history of depression, history of seizures, epilepsy, CNS anomalies or tumours, cerebrovascular disorders, upper or lower urinary tract obstruction, metastatic vertebral lesions; at high risk for metabolic or CV diseases. Treatment guidelines may vary among individual products (refer to product-specific recommendations). Children (particularly those with progressive brain tumours). Monitoring Parameters Prior to treatment initiation: Confirm pregnancy status, premenopausal status following chemotherapy (irrespective of menstrual status), ovarian suppression by low blood concentrations of FSH and estradiol, bone mineral density. Monitor blood glucose levels and HbA1c periodically; blood pressure, electrolytes and ECG regularly in at-risk patients; signs and symptoms of hypersensitivity reactions, emerging CV disease, and worsening/developing psychiatric symptoms. For treatment of prostate cancer, monitor serum testosterone levels and prostate-specific antigen.
Adverse Reactions
Significant: QT/QTc interval prolongation, reduced bone mineral density with prolonged use (e.g. osteoporosis, bone fractures), hyperglycaemia, diabetes, hypertension, seizures, psychiatric effects (e.g. depression, mood changes, crying, irritability, aggression, impatience, anger), urethral obstruction, tumour flare, transiently increased serum testosterone levels, increased lymphocyte count, hypersensitivity reactions (e.g. angioedema, anaphylactic shock). Rarely, ovarian hyperstimulation syndrome (OHSS), pituitary apoplexy (secondary to pituitary adenoma). Gastrointestinal disorders: Nausea, abdominal pain or discomfort, dry mouth. General disorders and administration site conditions: Asthenia, fatigue, irritability, oedema, inj site reactions (e.g. pain, erythema, inflammation). Investigations: Increased weight. Musculoskeletal and connective tissue disorders: Bone pain, back pain, pain in the extremity, myalgia, arthralgia, muscle spasms. Nervous system disorders: Headache, paraesthesia, dizziness. Psychiatric disorders: Sleep disorder, insomnia, nervousness. Renal and urinary disorders: Dysuria, urinary incontinence. Reproductive system and breast disorders: Erectile dysfunction, loss of libido, decreased libido, gynaecomastia, impotence, vaginal haemorrhage, vulvovaginal dryness, dysmenorrhoea, pelvic pain, dyspareunia, ovarian hypertrophy, breast pain or disorder, vaginal bleeding. Skin and subcutaneous tissue disorders: Hyperhidrosis, acne, seborrhoea. Vascular disorders: Hot flushes, embolism.
Potentially Fatal: MI, sudden cardiac death, stroke, spinal cord compression.
Drug Interactions
May increase risk of QT interval prolongation with agents known to induce torsades de pointes or prolong QT interval (e.g. quinidine, disopyramide, sotalol, amiodarone, methadone, moxifloxacin, antipsychotics). May reduce the level of GnRH receptors in the pituitary with drugs known to increase prolactin levels.
CIMS Class
Hormonal Chemotherapy / Trophic Hormones & Related Synthetic Drugs
ATC Classification
L02AE04 - triptorelin ; Belongs to the class of gonadotropin releasing hormone analogues. Used in endocrine therapy.
Disclaimer: This information is independently developed by CIMS based on triptorelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in